Matthew V. Lorenzi

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li et al. · Cell · 2018 · 1.1K citations · Full text

Kras Mutant Cancers, Medicine, Anti-cancer Agent +6

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec et al. · Molecular Cancer Therapeutics · 2017 · 335 citations · Full text

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion–Driven NSCLC

Jiyeon Yun, Soo‐Hwan Lee, Seok‐Young Kim et al. · Cancer Discovery · 2020 · 272 citations · Full text

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor–Resistant Lung Tumors

Sheri L. Moores, Mark L. Chiu, Barbara S. Bushey et al. · Cancer Research · 2016 · 262 citations

Cmet Is Effective, Medicine, Receptor Tyrosine Kinase +15

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Xu‐Chao Zhang, Jun Wang, Guoguang Shao et al. · Nature Communications · 2019 · 225 citations · Full text